David Garrison has been promoted from chief financial officer to executive vice president of finance and CFO for Arrhythmia Research Technology (ART; Fitchburg, Massachusetts). ART, through its wholly owned subsidiary, Micron Products, produces silver plated sensors and distributes metal snaps for manufacturers of disposable ECG electrodes and Micron's NEM division manufactures injection molded products for medical, electronic, industrial and consumer applications. Its products also include proprietary signal-averaging electrocardiographic software used in the detection of potentially lethal heart arrhythmias.
Boston Scientific (Natick, Massachusetts) reported an expansion of its management structure that includes the promotion of Paul LaViolette to chief operating officer. LaViolette has served in several positions since joining the company in 1994, most recently as senior vice president and group president for Boston Sci's cardiovascular business. In his new post, he will assume responsibility for all of the company's business units and worldwide commercial activities, with the exception of the recently acquired Advanced Bionics. Among his new responsibilities will be the company's Endosurgery Group, which will continue to be managed by Steve Moreci, senior vice president and group president for endosurgery. LaViolette also will share responsibility for manufacturing activities, which will continue to report to Jim Taylor, executive vice president for operations, and research and development, which will continue to report to Fred Colen, executive vice president and chief technology officer. Several other executives have been promoted and named to the company's Executive Committee. They include Brian Burns, senior vice president for quality; Jeff Goodman: senior vice president and president of International; Ken Pucel, senior vice president for operations; and Dr. Mary Russell, senior vice president for clinical and regulatory and chief medical officer. Goodman previously was president of Inter-Continental, which includes all countries outside the U.S., Europe and Japan. Russell previously was senior VP and chief medical officer for cardiovascular clinical sciences. She assumes responsibility for regulatory affairs from Dennis Ocwieja, who is retiring. In another appointment, Jim Gilbert is joining Boston Scientific as a senior vice president and member of the Executive Committee. He will have broad responsibilities, providing strategic support on key projects and growth initiatives and managing corporate e-marketing, corporate marketing science, corporate sales and national accounts, and reimbursement and outcomes planning. Gilbert joins Boston Sci after 23 years at Bain and Co., where he was managing partner of Bain's Global Healthcare Practice. Hank Kucheman has been promoted to president of the company's interventional cardiology business after most recently serving as senior vice president for cardiovascular and corporate marketing. Existing members of the Executive Committee who have received promotions include Larry Best, now executive vice president for finance and administration and CFO; Fred Colen: executive VP and chief technology officer; Paul Donovan: senior vice president for corporate communications; Bob MacLean, executive VP for human resources; Paul Sandman, executive VP, secretary and general counsel; and Taylor, executive VP for operations.
Robert Saltmarsh has been named CFO of Nanogen (San Diego). Saltmarsh joined Nanogen as vice president of corporate development last September. In addition to participating in business development initiatives, he assumed oversight of all financial operations and investor relations for the company. Nanogen makes the NanoChip Molecular Biology Workstation, NanoChip Electronic Microarray and a suite of analyte-specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases.
Thoratec (Pleasanton, California) said M. Wayne Boylston, senior vice president and CFO, has resigned for personal reasons. The company said Boylston will provide assistance during the transition period. Thoratec develops products to treat cardiovascular disease, primarily its Thoratec ventricular assist device and HeartMate left ventricular assist system.